Publicaciones en las que colabora con PATRYCJA MICHALSKA DZIAMA (27)

2024

  1. TRP14 is the rate-limiting enzyme for intracellular cystine reduction and regulates proteome cysteinylation

    EMBO Journal, Vol. 43, Núm. 13, pp. 2789-2812

  2. The Melatonin Derivative ITH13001 Prevents Hypertension and Cardiovascular Alterations in Angiotensin II-Infused Mice

    The Journal of pharmacology and experimental therapeutics, Vol. 388, Núm. 2, pp. 670-687

2022

  1. Enantioselective Synthesis and Pharmacological Evaluation of Aza‐CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease

    Antioxidants, Vol. 11, Núm. 1

  2. Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease

    Antioxidants, Vol. 11, Núm. 2

  3. Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4727-4751

2021

  1. Bisavenathramide analogues as nrf2 inductors and neuroprotectors in in vitro models of oxidative stress and hyperphosphorylation

    Antioxidants, Vol. 10, Núm. 6

  2. Enhanced stability and bioactivity of natural anticancer topoisomerase i inhibitors through cyclodextrin complexation

    Pharmaceutics, Vol. 13, Núm. 10

2020

  1. Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease

    Antioxidants, Vol. 9, Núm. 8, pp. 1-20

  2. Aza-CGP37157-lipoic hybrids designed as novel Nrf2-inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties

    Drug Development Research, Vol. 81, Núm. 3, pp. 283-294

  3. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization

    Pharmacological Research, Vol. 152

  4. New Nrf2-inducer compound ITH12674 slows the progression of retinitis pigmentosa in the mouse model rd10

    Cellular Physiology and Biochemistry, Vol. 54, Núm. 1, pp. 142-159

  5. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

    European Journal of Medicinal Chemistry, Vol. 190

  6. When it comes to an end: Oxidative stress crosstalk with protein aggregation and neuroinflammation induce neurodegeneration

    Antioxidants, Vol. 9, Núm. 8, pp. 1-34

2019

  1. Nrf2 plays a protective role against intravascular hemolysis-mediated acute kidney injury

    Frontiers in Pharmacology, Vol. 10

  2. Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux

    Journal of Pineal Research, Vol. 67, Núm. 1

  3. The angiotensin-(1-7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation

    Aging Cell, Vol. 18, Núm. 3

2018

  1. MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species

    Translational Research, Vol. 200, pp. 1-17

2017

  1. Addition to "ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia"

    ACS chemical neuroscience, Vol. 8, Núm. 1, pp. 210

  2. Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease

    Scientific Reports, Vol. 7

  3. ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia

    ACS Chemical Neuroscience, Vol. 8, Núm. 1, pp. 67-81